Fulgent Genetics (FLGT) Stock Overview
Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
FLGT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fulgent Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.13 |
| 52 Week High | US$31.04 |
| 52 Week Low | US$13.46 |
| Beta | 0.89 |
| 1 Month Change | -14.05% |
| 3 Month Change | -46.07% |
| 1 Year Change | -31.21% |
| 3 Year Change | -58.36% |
| 5 Year Change | -81.07% |
| Change since IPO | 53.92% |
Recent News & Updates
Fulgent Genetics: A Major Market Misconception
Mar 12
FLGT: Higher Future P/E Assumptions Will Support Margin Driven Bullish Outlook
Analysts have lifted their price target on Fulgent Genetics by $2, reflecting updated assumptions around discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent adjustments to the Fulgent Genetics price target reflect updated thinking on how the company might balance profitability, growth investments, and valuation multiples over time.Recent updates
Fulgent Genetics: A Major Market Misconception
Mar 12FLGT: Higher Future P/E Assumptions Will Support Margin Driven Bullish Outlook
Analysts have lifted their price target on Fulgent Genetics by $2, reflecting updated assumptions around discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent adjustments to the Fulgent Genetics price target reflect updated thinking on how the company might balance profitability, growth investments, and valuation multiples over time.
FLGT: Higher Future P/E Assumptions Will Support Long Term Upside
Analysts have lifted their fair value estimate for Fulgent Genetics from $21.00 to $30.00, citing updated assumptions about revenue growth, profit margins, and a higher future P/E multiple to support the new price target range. Analyst Commentary While the higher fair value estimate for Fulgent Genetics reflects more constructive assumptions, not every analyst is leaning in the same direction.FLGT: Raised 2025 Guidance And Share Buybacks Will Support Bullish Outlook
Analysts have maintained their price target on Fulgent Genetics, citing only very small adjustments to the discount rate, long-term revenue growth, profit margin expectations, and future P/E assumptions, rather than any major change in their overall view of the company. What's in the News From July 1, 2025 to September 30, 2025, Fulgent Genetics reported no share repurchases under its existing program, with 0 shares bought for US$0 million in that period (Key Developments).Health Check: How Prudently Does Fulgent Genetics (NASDAQ:FLGT) Use Debt?
Jan 08
FLGT: Raised Guidance And Oncology Trial Progress Will Support Upside Potential
Analysts have maintained their price target for Fulgent Genetics at US$36.00, indicating relatively unchanged fair value and discount rate assumptions, along with slightly revised expectations for revenue growth, profit margin, and future P/E. What's in the News From July 1, 2025 to September 30, 2025, Fulgent Genetics reported no share repurchases under its existing program.FLGT: Improved Profit Outlook And Pipeline Progress Will Support Upside Potential
Analysts have raised their price target on Fulgent Genetics from 30 dollars to 36 dollars, citing slightly improved long term profit margin expectations and a higher projected future price to earnings multiple, despite more conservative revenue growth assumptions and a modestly higher discount rate. What's in the News Raised full year 2025 guidance, now expecting approximately 325 million dollars in revenue and a GAAP loss of about 1.70 dollars per share, indicating increased confidence in the core business trajectory (Key Developments).FLGT: Raised 2025 Guidance And Trial Progress Will Support Bullish Outlook
Analysts maintained their price target on Fulgent Genetics at approximately 33.67 dollars, citing largely unchanged expectations for revenue growth and valuation multiples, despite a modest reduction in projected profit margins. What's in the News Raised full year 2025 earnings guidance, now expecting approximately 325 million dollars in revenue and a GAAP loss of about 1.70 dollars per share, signaling improved visibility into core business trends (company guidance) Reported preliminary phase 2 clinical data for FID-007 in combination with cetuximab as a second line treatment for recurrent or metastatic head and neck squamous cell carcinoma, with results to be presented at the ESMO 2025 meeting in Berlin (company clinical update) Highlighted that FID-007 nanoparticles are smaller than solvent based PTX micelles, which enables deeper tumor penetration, slower clearance, and higher intratumoral accumulation due to the enhanced permeability and retention effect (company clinical update) Valuation Changes Fair Value Estimate remained unchanged at approximately 33.67 dollars per share, indicating no material shift in intrinsic value assumptions.FLGT: Earnings Outlook And Clinical Data May Define Performance In 2025
Narrative Update on Fulgent Genetics Analyst Price Target Analysts have raised their price target for Fulgent Genetics from $27.00 to $33.67. This change is attributed to improved revenue growth and higher forecasted profit margins.FLGT: Full-Year Guidance And Early Clinical Data Will Shape 2025 Outlook
Analysts have raised their price target for Fulgent Genetics from $25.33 to $27.00, citing slightly improved profit margin projections as well as updated market expectations. What's in the News Fulgent Genetics raised its earnings guidance for the full year 2025, expecting revenue of approximately $325 million and improving its EPS guidance to a GAAP loss of approximately $1.70 per share.Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price Is Out Of Tune With Revenues
Nov 08Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Is On The Mark
Aug 06Enhanced Whole Genome Sequencing Will Open New Global Markets
Fulgent Genetics’ fair value has been revised upward, primarily reflecting improved consensus revenue growth forecasts and a higher future P/E multiple, with the analyst price target rising from $22.67 to $25.33. What's in the News Fulgent Genetics expects core revenue of approximately $320 million for full year 2025.Here's Why It's Unlikely That Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Will See A Pay Rise This Year
May 09Is Fulgent Genetics (NASDAQ:FLGT) Using Too Much Debt?
May 05
Laboratory, Pathology And Therapeutics Will Expand Future Capabilities
Fulgent Genetics' laboratory services success and sales team's efficiency improvements should drive revenue growth and improve gross margins.Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
Mar 20Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Jan 15Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade)
Dec 18Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Sep 25Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Sep 09Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio
Jul 17Fulgent Genetics: Growth Is Returning
Jun 06Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
May 10Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 07Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Shareholder Returns
| FLGT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -13.4% | 3.5% | 0.8% |
| 1Y | -31.2% | -3.2% | 27.7% |
Return vs Industry: FLGT underperformed the US Healthcare industry which returned -2.3% over the past year.
Return vs Market: FLGT underperformed the US Market which returned 28.7% over the past year.
Price Volatility
| FLGT volatility | |
|---|---|
| FLGT Average Weekly Movement | 12.5% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: FLGT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FLGT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,315 | Ming Hsieh | www.fulgentgenetics.com |
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Fulgent Genetics, Inc. Fundamentals Summary
| FLGT fundamental statistics | |
|---|---|
| Market cap | US$438.15m |
| Earnings (TTM) | -US$60.51m |
| Revenue (TTM) | US$322.67m |
Is FLGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLGT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.10 |
| Gross Margin | 40.56% |
| Net Profit Margin | -18.75% |
| Debt/Equity Ratio | 0.2% |
How did FLGT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/01 19:08 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fulgent Genetics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karen Koski | BTIG |
| Andrew Cooper | CGS International |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |